Drugs / CY150112
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04839926 | Mar → Aug 2021 | schizophrenia | Jiangsu Nhwa Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CY150112 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04839926 ↗ |
| Route | Oral | “single oral CY150112 while fasting on day 1.” NCT04839926 ↗ |